Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.
Department of Pharmacy and Biotechnology, Food Chemistry and Nutraceutical Lab, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy.
Int J Mol Sci. 2024 Aug 3;25(15):8486. doi: 10.3390/ijms25158486.
Nitric oxide (NO) has been defined as the "miracle molecule" due to its essential pleiotropic role in living systems. Besides its implications in physiologic functions, it is also involved in the development of several disease states, and understanding this ambivalence is crucial for medicinal chemists to develop therapeutic strategies that regulate NO production without compromising its beneficial functions in cell physiology. Although nitric oxide synthase (NOS), i.e., the enzyme deputed to the NO biosynthesis, is a well-recognized druggable target to regulate NO bioavailability, some issues have emerged during the past decades, limiting the progress of NOS modulators in clinical trials. In the present review, we discuss the most promising advancements in the research of small molecules that are able to regulate NOS activity with improved pharmacodynamic and pharmacokinetic profiles, providing an updated framework of this research field that could be useful for the design and development of new NOS modulators.
一氧化氮(NO)因其在生命系统中的重要多效作用而被定义为“神奇分子”。除了在生理功能中的意义外,它还涉及到几种疾病状态的发展,理解这种矛盾对于药物化学家开发调节 NO 产生的治疗策略至关重要,而不会损害其在细胞生理学中的有益功能。尽管一氧化氮合酶(NOS),即负责 NO 生物合成的酶,是一种公认的可调节药物靶点,可以调节 NO 的生物利用度,但在过去几十年中出现了一些问题,限制了 NOS 调节剂在临床试验中的进展。在本综述中,我们讨论了小分子在调节 NOS 活性方面最有前途的进展,这些小分子具有改善的药效学和药代动力学特性,为该研究领域提供了一个更新的框架,这可能有助于设计和开发新的 NOS 调节剂。